Kodiak Sciences scraps development of eye disorder drug
July 24 (Reuters) - Kodiak Sciences Inc KOD.O said on Monday it has decided to discontinue further development of its experimental drug to treat a type of eye disorder. (Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar) ((Mariam.ESunny@thomsonreuters.com;))
Recent news on Kodiak Sciences
See all newsBrief: Kodiak Sciences Inc. Files For Mixed Shelf Offering Size Not Disclosed - SEC Filing
US RESEARCH ROUNDUP-Acuity, Dell Technologies, Nike
Ocular Therapeutix tumbles on rival Kodiak's trial win, analyst calls selloff overdone
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX